A report from the Heart Failure Society of America indicates a concerning trend in the United States regarding heart failure prevalence and mortality. The estimated prevalence of heart failure among U.S. adults is currently 3%, projected to rise to 3.2% by 2030, 3.6% by 2040, and 3.8% by 2050, largely due to an aging population and increasing rates of obesity, hypertension, and cardiometabolic risk factors. Approximately one in four Americans are expected to develop heart failure in their lifetimes.
Age-adjusted mortality rates have increased by approximately 37% from 2010 to 2023, reversing prior progress. **SGLT2** is a critical component of guideline-directed medical therapy, but its utilization is understudied, with only 18% of patients with heart failure with reduced ejection fraction receiving these treatments. There is a need to improve the initiation and long-term use of these therapies.
Furthermore, hospitalization rates are rising among younger adults (25-44 and 45-64 years) despite declining rates in older adults (65 and older). The report emphasizes the importance of risk factor screening and control in early adulthood, alongside addressing racial and geographic disparities in care. The authors urge commitment across disciplines to reverse these trends and begin immediate action.